Kamada Ltd.(KMDA)Earnings, Financials & Key Ratios
KMDA•NASDAQ
$8.26
$476M mkt cap·22.3× P/E·Price updated May 7, 2026
AboutKamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Show more
- Revenue$195M+21.4%
- EBITDA$45M+31.6%
- Net Income$22M+51.2%
- EPS (Diluted)0.37+48.0%
- Gross Margin40.08%-7.8%
- EBITDA Margin22.8%+8.4%
- Operating Margin14.54%+16.7%
- Net Margin11.19%+24.6%
- ROE8.27%+44.0%
- ROIC10.72%+38.8%
- Debt/Equity0.04+0.8%
- Interest Coverage30.36
KMDA Key Insights
Kamada Ltd. (KMDA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 2.6%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
KMDA Price & Volume
Kamada Ltd. (KMDA) stock price & volume — 10-year historical chart
Loading chart...
KMDA Growth Metrics
Kamada Ltd. (KMDA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.79%
5 Years7.95%
3 Years14.73%
TTM12.69%
Profit CAGR
10 Years-
5 Years4.99%
3 Years-
TTM40.17%
EPS CAGR
10 Years-
5 Years-2.03%
3 Years-
TTM33.82%
Return on Capital
10 Years6.97%
5 Years4.03%
3 Years6.24%
Last Year8.68%
KMDA Recent Earnings
Kamada Ltd. (KMDA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
Mar 11, 2026EPS
$0.06
Est $0.09
-33.3%
Revenue
$45M
Est $45M
-1.6%
Q4 2025
Nov 10, 2025EPS
$0.09
Est $0.10
-10.0%
Revenue
$47M
Est $148M
-68.1%
Q3 2025
Aug 13, 2025EPS
$0.13
Est $0.09
+44.4%
Revenue
$45M
Est $155M
-71.1%
Q2 2025
May 14, 2025EPS
$0.07
Est $0.07
+0.0%
Revenue
$44M
Est $162M
-72.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 11, 2026 | $0.06vs $0.09-33.3% | $45Mvs $45M-1.6% |
| Q4 2025 | Nov 10, 2025 | $0.09vs $0.10-10.0% | $47Mvs $148M-68.1% |
| Q3 2025 | Aug 13, 2025 | $0.13vs $0.09+44.4% | $45Mvs $155M-71.1% |
| Q2 2025 | May 14, 2025 | $0.07vs $0.07+0.0% | $44Mvs $162M-72.8% |
Based on last 12 quarters of dataView full earnings history →
KMDA Peer Comparison
Kamada Ltd. (KMDA) competitors in Vaccines and biodefense products — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ADMA | 2.03B | 8.47 | 14.12 | 19.63% | 32.43% | 38.97% | 0.17 | |
 GRFS | 6.82B | 8.06 | 12.03 | 0.2% | 5.34% | 5.16% | 1.15 | |
 BIO | 6.95B | 257.32 | 9.23 | 0.65% | 6.52% | 2.4% | 0.21 | |
 BHVN | 1.03B | 9.74 | -1.42 | -8.66% | 5.36 | |||
 RARE | 2.57B | 26.13 | -4.48 | 20.13% | -91.03% | -6.08% | ||
 PRTA | 566.86M | 10.53 | -2.32 | -92.84% | -260.92% | -49.88% | 0.05 | |
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 |
Compare KMDA vs Peers
Kamada Ltd. (KMDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KMDA Income Statement
Kamada Ltd. (KMDA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 102.83M | 114.47M | 127.19M | 133.25M | 103.64M | 129.34M | 142.52M | 160.95M | 195.34M |
| Revenue Growth % | 32.69% | 11.32% | 11.11% | 4.76% | -22.22% | 24.79% | 10.19% | 12.93% | 21.37% |
| Cost of Goods Sold | 70.74M | 73M | 77.45M | 85.69M | 73.31M | 82.64M | 87.03M | 90.99M | 117.06M |
| COGS % of Revenue | 68.79% | 63.77% | 60.89% | 64.31% | 70.74% | 63.89% | 61.06% | 56.53% | 59.92% |
| Gross Profit | 32.09M▲ 0% | 41.47M▲ 29.2% | 49.74M▲ 19.9% | 47.55M▼ 4.4% | 30.33M▼ 36.2% | 46.7M▲ 54.0% | 55.49M▲ 18.8% | 69.97M▲ 26.1% | 78.28M▲ 11.9% |
| Gross Margin % | 31.21% | 36.23% | 39.11% | 35.69% | 29.26% | 36.11% | 38.94% | 43.47% | 40.08% |
| Gross Profit Growth % | 48.21% | 29.24% | 19.93% | -4.39% | -36.22% | 53.99% | 18.81% | 26.09% | 11.89% |
| Operating Expenses | 24.64M | 22.21M | 26.95M | 28.32M | 31.02M | 42.17M | 45.43M | 49.92M | 49.89M |
| OpEx % of Revenue | 23.97% | 19.41% | 21.19% | 21.25% | 29.93% | 32.61% | 31.87% | 31.01% | 25.54% |
| Selling, General & Admin | 12.67M | 12.15M | 12.85M | 14.66M | 17.55M | 25.06M | 27.45M | 30.83M | 36.63M |
| SG&A % of Revenue | 12.32% | 10.62% | 10.1% | 11% | 16.93% | 19.37% | 19.26% | 19.16% | 18.75% |
| Research & Development | 11.97M | 9.75M | 13.06M | 13.61M | 11.36M | 13.17M | 13.93M | 15.19M | 13.26M |
| R&D % of Revenue | 11.64% | 8.52% | 10.27% | 10.21% | 10.96% | 10.18% | 9.78% | 9.43% | 6.79% |
| Other Operating Expenses | 0 | 997K | 1.05M | 49K | 2.12M | 3.94M | 4.04M | 3.9M | 0 |
| Operating Income | 7.44M▲ 0% | 19.26M▲ 158.7% | 22.78M▲ 18.3% | 19.24M▼ 15.6% | -696K▼ 103.6% | 4.53M▲ 751.1% | 10.06M▲ 122.1% | 20.05M▲ 99.2% | 28.4M▲ 41.6% |
| Operating Margin % | 7.24% | 16.82% | 17.91% | 14.44% | -0.67% | 3.5% | 7.06% | 12.46% | 14.54% |
| Operating Income Growth % | 227.44% | 158.72% | 18.3% | -15.57% | -103.62% | 751.15% | 122.07% | 99.23% | 41.62% |
| EBITDA | 11.09M | 22.82M | 27.3M | 24.48M | 4.91M | 16.69M | 21.53M | 33.86M | 44.54M |
| EBITDA Margin % | 10.79% | 19.94% | 21.47% | 18.37% | 4.74% | 12.9% | 15.11% | 21.04% | 22.8% |
| EBITDA Growth % | 546.69% | 105.71% | 19.64% | -10.33% | -79.93% | 239.65% | 29.05% | 57.24% | 31.55% |
| D&A (Non-Cash Add-back) | 3.65M | 3.56M | 4.52M | 5.25M | 5.61M | 12.15M | 11.47M | 13.81M | 16.15M |
| EBIT | 7.6M | 19.9M | 23.27M | 20.17M | -1.6M | -1.34M | 10.06M | 13.99M | 28.4M |
| Net Interest Income | 418K | 461.82K | 853K | 761K | 12K | -823K | -710K | 1.46M | 1.14M |
| Interest Income | 500K | 788.95K | 1.15M | 1.03M | 295K | 91K | 588K | 2.12M | 2.08M |
| Interest Expense | 82K | 327.13K | 293K | 266K | 283K | 914K | 1.3M | 660K | 935.25K |
| Other Income/Expense | -274K | 1.08M | 197K | -672K | -1.19M | -6.79M | -1.64M | -6.72M | -2.99M |
| Pretax Income | 7.17M▲ 0% | 20.34M▲ 183.7% | 22.98M▲ 13.0% | 18.57M▼ 19.2% | -1.89M▼ 110.2% | -2.26M▼ 19.8% | 8.43M▲ 473.1% | 13.33M▲ 58.2% | 25.4M▲ 90.5% |
| Pretax Margin % | 6.97% | 17.77% | 18.07% | 13.93% | -1.82% | -1.75% | 5.91% | 8.28% | 13% |
| Income Tax | 269K | -1.96M | 730K | 1.43M | 345K | 62K | 145K | -1.13M | 3.54M |
| Effective Tax Rate % | 3.75% | -9.61% | 3.18% | 7.68% | -18.3% | -2.74% | 1.72% | -8.46% | 13.93% |
| Net Income | 6.9M▲ 0% | 22.3M▲ 223.1% | 22.25M▼ 0.2% | 17.14M▼ 23.0% | -2.23M▼ 113.0% | -2.32M▼ 4.1% | 8.28M▲ 456.9% | 14.46M▲ 74.6% | 21.86M▲ 51.2% |
| Net Margin % | 6.71% | 19.48% | 17.49% | 12.86% | -2.15% | -1.79% | 5.81% | 8.99% | 11.19% |
| Net Income Growth % | 202.5% | 223.08% | -0.2% | -22.97% | -113.01% | -4.08% | 456.92% | 74.58% | 51.18% |
| Net Income (Continuing) | 6.9M | 22.3M | 22.25M | 17.14M | -2.23M | -2.32M | 8.28M | 14.46M | 21.86M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.18▲ 0% | 0.55▲ 205.6% | 0.57▲ 3.6% | 0.41▼ 28.1% | -0.05▼ 112.1% | -0.05▼ 4.0% | 0.15▲ 389.6% | 0.25▲ 66.7% | 0.37▲ 48.0% |
| EPS Growth % | 200% | 205.56% | 3.64% | -28.07% | -112.15% | -4.02% | 389.58% | 66.67% | 48% |
| EPS (Basic) | 0.18 | 0.55 | 0.57 | 0.42 | -0.05 | -0.05 | 0.17 | 0.25 | 0.38 |
| Diluted Shares Outstanding | 38.05M | 40.54M | 40.58M | 44.59M | 44.77M | 44.82M | 53.68M | 57.82M | 58.35M |
| Basic Shares Outstanding | 37.97M | 40.28M | 40.32M | 44.14M | 44.77M | 44.82M | 48.83M | 57.49M | 57.65M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | 57.1% |
KMDA Balance Sheet
Kamada Ltd. (KMDA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 96.88M | 110.89M | 143.56M | 177.91M | 130.04M | 139M | 169.96M | 184.35M | 193.12M |
| Cash & Short-Term Investments | 43.02M | 50.59M | 73.91M | 109.27M | 18.59M | 34.26M | 55.64M | 78.44M | 75.48M |
| Cash Only | 12.68M | 18.09M | 42.66M | 70.2M | 18.59M | 34.26M | 55.64M | 78.44M | 75.48M |
| Short-Term Investments | 30.34M | 32.5M | 31.25M | 39.07M | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 31.97M | 29.5M | 25.23M | 23.05M | 35.56M | 28.36M | 21.29M | 23.2M | 29.05M |
| Days Sales Outstanding | 113.49 | 94.06 | 72.4 | 63.15 | 125.24 | 80.02 | 54.52 | 52.6 | 54.27 |
| Inventory | 21.07M | 29.32M | 43.17M | 43.04M | 71.83M | 72.52M | 88.48M | 78.82M | 84.96M |
| Days Inventory Outstanding | 108.72 | 146.59 | 203.46 | 183.33 | 357.61 | 320.3 | 371.08 | 316.19 | 264.92 |
| Other Current Assets | 0 | 0 | 15K | 448K | 73K | 0 | 149K | 49K | 0 |
| Total Non-Current Assets | 25.23M | 27.23M | 30.23M | 32.75M | 188.62M | 183.37M | 184.94M | 187.91M | 185.67M |
| Property, Plant & Equipment | 25.18M | 25M | 28.57M | 29.12M | 29.4M | 28.73M | 35.98M | 45.86M | 50.28M |
| Fixed Asset Turnover | 4.08x | 4.58x | 4.45x | 4.58x | 3.53x | 4.50x | 3.96x | 3.51x | 3.89x |
| Goodwill | 0 | 0 | 0 | 0 | 30.31M | 30.31M | 30.31M | 30.31M | 30.32M |
| Intangible Assets | 0 | 123K | 298K | 1.49M | 123.28M | 116.7M | 109.64M | 101.86M | 96.12M |
| Long-Term Investments | 0 | -123K | 0 | 0 | 0 | 0 | 0 | 0 | 7.55M |
| Other Non-Current Assets | 49K | 174K | 54K | 2.14M | 5.63M | 7.64M | 9.01M | 9.38M | 1.42M |
| Total Assets | 122.11M▲ 0% | 138.12M▲ 13.1% | 173.8M▲ 25.8% | 210.66M▲ 21.2% | 318.67M▲ 51.3% | 322.38M▲ 1.2% | 354.91M▲ 10.1% | 372.25M▲ 4.9% | 378.79M▲ 1.8% |
| Asset Turnover | 0.84x | 0.83x | 0.73x | 0.63x | 0.33x | 0.40x | 0.40x | 0.43x | 0.52x |
| Asset Growth % | 22.48% | 13.11% | 25.83% | 21.21% | 51.27% | 1.16% | 10.09% | 4.89% | 1.76% |
| Total Current Liabilities | 29.4M | 23.57M | 32.74M | 24.97M | 54.06M | 75.7M | 49.59M | 49.39M | 47.4M |
| Accounts Payable | 18.04M | 17.29M | 24.83M | 16.11M | 25.1M | 32.92M | 24.8M | 27.73M | 23.25M |
| Days Payables Outstanding | 93.06 | 86.43 | 117.02 | 68.62 | 124.98 | 145.39 | 104.03 | 111.26 | 72.49 |
| Short-Term Debt | 614K | 452K | 489K | 238K | 2.63M | 4.44M | 0 | 0 | 2.12M |
| Deferred Revenue (Current) | 4.93M | 461K | 589K | 222K | 247K | 236K | 325K | 171K | 0 |
| Other Current Liabilities | 1.08M | 553K | 5.67M | 7.03M | 24.33M | 36.48M | 22.54M | 19.4M | 11.77M |
| Current Ratio | 3.30x | 4.70x | 4.39x | 7.13x | 2.41x | 1.84x | 3.43x | 3.73x | 4.07x |
| Quick Ratio | 2.58x | 3.46x | 3.07x | 5.40x | 1.08x | 0.88x | 1.64x | 2.14x | 2.28x |
| Cash Conversion Cycle | 129.15 | 154.21 | 158.84 | 177.86 | 357.87 | 254.93 | 321.57 | 257.53 | 246.7 |
| Total Non-Current Liabilities | 3.22M | 2.17M | 5.74M | 7.06M | 87.79M | 70.65M | 61.29M | 63.4M | 62.26M |
| Long-Term Debt | 1.37M | 688K | 257K | 36K | 17.41M | 12.96M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 28K | 3.98M | 3.59M | 3.16M | 2.18M | 7.44M | 9.43M | 9.44M |
| Deferred Tax Liabilities | 21.06M | 16.92M | 0 | 0 | 0 | 0 | 0 | 0 | 1.65M |
| Other Non-Current Liabilities | 1.14M | 787K | 1.27M | 1.41M | 67.2M | 55.51M | 53.85M | 53.97M | 51.17M |
| Total Liabilities | 32.62M | 25.74M | 38.48M | 32.03M | 141.84M | 146.36M | 110.89M | 112.79M | 109.66M |
| Total Debt | 1.98M | 1.28M | 5.75M | 4.94M | 24.35M | 20.6M | 8.82M | 11.06M | 11.56M |
| Net Debt | -10.7M | -16.82M | -36.91M | -65.26M | 5.76M | -13.66M | -46.82M | -67.37M | -63.92M |
| Debt / Equity | 0.02x | 0.01x | 0.04x | 0.03x | 0.14x | 0.12x | 0.04x | 0.04x | 0.04x |
| Debt / EBITDA | 0.18x | 0.06x | 0.21x | 0.20x | 4.96x | 1.23x | 0.41x | 0.33x | 0.26x |
| Net Debt / EBITDA | -0.96x | -0.74x | -1.35x | -2.67x | 1.17x | -0.82x | -2.17x | -1.99x | -1.44x |
| Interest Coverage | 90.78x | 58.87x | 77.76x | 72.32x | -2.46x | 4.96x | 7.75x | 30.38x | 30.36x |
| Total Equity | 89.49M▲ 0% | 112.38M▲ 25.6% | 135.32M▲ 20.4% | 178.64M▲ 32.0% | 176.82M▼ 1.0% | 176.02M▼ 0.5% | 244.02M▲ 38.6% | 259.46M▲ 6.3% | 269.13M▲ 3.7% |
| Equity Growth % | 34.08% | 25.57% | 20.42% | 32.01% | -1.02% | -0.45% | 38.63% | 6.33% | 3.72% |
| Book Value per Share | 2.35 | 2.77 | 3.33 | 4.01 | 3.95 | 3.93 | 4.55 | 4.49 | 4.61 |
| Total Shareholders' Equity | 89.49M | 112.38M | 135.32M | 178.64M | 176.82M | 176.02M | 244.02M | 259.46M | 269.13M |
| Common Stock | 10.4M | 10.41M | 10.43M | 11.71M | 11.72M | 11.73M | 15.02M | 15.03M | 15.08M |
| Retained Earnings | -104.56M | -83.02M | -61.07M | -43.93M | -46.16M | -48.48M | -40.2M | -25.74M | -17.08M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -3.79M | -3.51M | -3.7M | -3.45M | -3.58M | -3.23M | -3.08M | -3.08M | 2.78M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KMDA Cash Flow Statement
Kamada Ltd. (KMDA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 3.89M | 10.55M | 28.44M | 19.11M | -9.17M | 28.59M | 4.32M | 47.59M | 27.59M |
| Operating CF Margin % | 3.78% | 9.21% | 22.36% | 14.34% | -8.85% | 22.1% | 3.03% | 29.57% | 14.12% |
| Operating CF Growth % | 105.06% | 171.11% | 169.69% | -32.83% | -147.98% | 411.82% | -84.91% | 1002.99% | -42.03% |
| Net Income | 6.9M | 22.3M | 22.95M | 17.14M | -2.32M | -2.32M | 8.28M | 14.46M | 21.86M |
| Depreciation & Amortization | 3.52M | 3.7M | 4.66M | 4.9M | 5.83M | 12.15M | 12.71M | 13.81M | 16.15M |
| Stock-Based Compensation | 483K | 948K | 0 | 977K | 0 | 1.15M | 1.31M | 874K | 0 |
| Deferred Taxes | 269K | -1.96M | 748.91K | 1.43M | 0 | 62K | 145K | -1.13M | 0 |
| Other Non-Cash Items | 650K | -380K | 1.85M | 1.77M | 2.3M | 5.89M | 60K | 8.16M | 8.72M |
| Working Capital Changes | -7.94M | -14.07M | -1.77M | -7.1M | -14.98M | 11.65M | -18.2M | 11.41M | -19.14M |
| Change in Receivables | -9.97M | 2.31M | 5.06M | 1.45M | -15.07M | 5.68M | 9.5M | -908K | -5.92M |
| Change in Inventory | 4.52M | -8.25M | -14.29M | 1.16M | -2.47M | -1.36M | -19.69M | 9.66M | -6.63M |
| Change in Payables | -556K | -1.12M | 6.46M | -9.56M | 8.23M | 7.05M | -8.88M | 1.23M | -7.44M |
| Cash from Investing | -15.89M | -5.18M | -581.8K | -13.13M | -63.46M | -3.78M | -5.84M | -10.74M | -10.65M |
| Capital Expenditures | -4.45M | -2.88M | -2.37M | -5.49M | -3.88M | -3.78M | -5.85M | -10.74M | -10.66M |
| CapEx % of Revenue | 4.33% | 2.52% | 1.87% | 4.12% | 3.74% | 2.93% | 4.1% | 6.67% | 5.46% |
| Acquisitions | 62.16K | 28.86K | 9.28K | 0 | -100.21M | 0 | 0 | 0 | 8.66K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -11.44M | -2.29M | 0 | 7K | 0 | 0 | 7K | 1K | 0 |
| Cash from Financing | 15.32M | -587K | -1.58M | 23.36M | 19.33M | -9.34M | 22.68M | -13.91M | -19.86M |
| Debt Issued (Net) | -251K | -596K | -491.02K | -1.59M | 20.58M | -3.73M | -18.26M | -1.25M | 0 |
| Equity Issued (Net) | 1000K | 0 | 16.5K | 1000K | 19.75K | 0 | 1000K | 0 | 54.12K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -12.49M |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 3K | 9K | -1.1M | 64K | -1.27M | -5.62M | -17.3M | -12.66M | -7.43M |
| Net Change in Cash | 2.71M▲ 0% | 5.41M▲ 99.5% | 24.57M▲ 354.0% | 27.54M▲ 12.1% | -51.58M▼ 287.3% | 15.67M▲ 130.4% | 21.38M▲ 36.4% | 22.79M▲ 6.6% | -2.95M▼ 112.9% |
| Free Cash Flow | -559K▲ 0% | 7.66M▲ 1470.7% | 26.07M▲ 240.2% | 13.62M▼ 47.8% | -13.04M▼ 195.8% | 24.8M▲ 290.1% | -1.53M▼ 106.2% | 36.85M▲ 2500.9% | 16.93M▼ 54.1% |
| FCF Margin % | -0.54% | 6.69% | 20.5% | 10.22% | -12.59% | 19.18% | -1.08% | 22.9% | 8.67% |
| FCF Growth % | 24.87% | 1470.66% | 240.23% | -47.76% | -195.8% | 290.13% | -106.19% | 2500.91% | -54.05% |
| FCF per Share | -0.01 | 0.19 | 0.64 | 0.31 | -0.29 | 0.55 | -0.03 | 0.64 | 0.29 |
| FCF Conversion (FCF/Net Income) | 0.56x | 0.47x | 1.28x | 1.11x | 4.11x | -12.32x | 0.52x | 3.29x | 1.26x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KMDA Key Ratios
Kamada Ltd. (KMDA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -9.67% | 8.83% | 22.09% | 17.97% | 10.92% | -1.25% | -1.32% | 3.94% | 5.74% | 8.27% |
| Return on Invested Capital (ROIC) | -6.94% | 8.13% | 16.57% | 17.62% | 13.63% | -0.35% | 1.97% | 4.2% | 7.73% | 10.72% |
| Gross Margin | 27.94% | 31.21% | 36.23% | 39.11% | 35.69% | 29.26% | 36.11% | 38.94% | 43.47% | 40.08% |
| Net Margin | -8.69% | 6.71% | 19.48% | 17.49% | 12.86% | -2.15% | -1.79% | 5.81% | 8.99% | 11.19% |
| Debt / Equity | 0.03x | 0.02x | 0.01x | 0.04x | 0.03x | 0.14x | 0.12x | 0.04x | 0.04x | 0.04x |
| Interest Coverage | -46.36x | 90.78x | 58.87x | 77.76x | 72.32x | -2.46x | 4.96x | 7.75x | 30.38x | 30.36x |
| FCF Conversion | -0.28x | 0.56x | 0.47x | 1.28x | 1.11x | 4.11x | -12.32x | 0.52x | 3.29x | 1.26x |
| Revenue Growth | 10.53% | 32.69% | 11.32% | 11.11% | 4.76% | -22.22% | 24.79% | 10.19% | 12.93% | 21.37% |
KMDA Frequently Asked Questions
Kamada Ltd. (KMDA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Kamada Ltd. (KMDA) reported $181.4M in revenue for fiscal year 2025. This represents a 1092% increase from $15.2M in 2008.
Kamada Ltd. (KMDA) grew revenue by 21.4% over the past year. This is strong growth.
Yes, Kamada Ltd. (KMDA) is profitable, generating $20.3M in net income for fiscal year 2025 (11.2% net margin).
Dividend & Returns
Yes, Kamada Ltd. (KMDA) pays a dividend with a yield of 2.59%. This makes it attractive for income-focused investors.
Kamada Ltd. (KMDA) has a return on equity (ROE) of 8.3%. This is below average, suggesting room for improvement.
Kamada Ltd. (KMDA) generated $15.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More KMDA
Kamada Ltd. (KMDA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates